Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 2 interim and final data of ATB200 for Pompe Disease due 2016

Source Link:: http://files.shareholder.com/downloads/AMTX/1329340265x0x869418/04daa14f-2c84-42e9-9052-1f7ab214f0b4/FOLD_News_2016_1_11_General.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

FOLD

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details

Data from clinical study ATB200-02 in initial ambulatory ERT-switch patients (Cohort 1) on track by year-end 2016

Additional ATB200-02 study data in naïve and non-ambulatory patients (Cohorts 2-3), as well as initial extension-phase data on ambulatory ERT-switch patients, throughout 1H17

http://ir.amicusrx.c...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Dec 08, 2016

Occurred Source:

http://ir.amicusrx.com/releasedetail.cfm?ReleaseID=1003339

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Final Data, Atb200, Pompe Disease, Oral Chaperone, At2221